Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Proteonomix Settles Litigation PR Newswire PARAMUS, N.J., April 1, 2013 PARAMUS, N.J., April 1, 2013 /PRNewswire/ -- Proteonomix, Inc. (OTC: PROT), a biotechnology company focused on developing...
Proteonomix Announces Extension Of Deadline /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt...
Proteonomix To Require Physical Exchange Of Certificates /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li {...
Proteonomix Announces Restructuring /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-f...
Proteonomix Updates Status Of UMK-121 Testing /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8...
Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121 /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; co...
Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Ari...
Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease Has Been Listed on ClinicalTrials.gov /* Style Definitions...
Proteonomix, Inc. Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease PR Newswire PARAMUS, N.J., Oct. 4, 2012 PARAMUS, N.J., Oct. 4, 2012...
Proteonomix, Inc. (OTC/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 100 | 1.0E-6 | CS |
| 26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 5067 | 1.0E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 3900 | 1.0E-6 | CS |
| 156 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 28662 | 7.369E-5 | CS |
| 260 | -0.006099 | -99.9836065574 | 0.0061 | 0.03 | 1.0E-6 | 19821 | 0.00622878 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
